Search Results
Showing 11 - 20 out of 300 Results
Advocacy and Issues
Letter of Support for the Mitigating Emergency Drug Shortages (MEDS) Act
The Honorable Susan Collins United States Senate Dirksen Building, #413 Washington, D.C. 20510 The Honorable Tina Smith United States Senate Hart Senate Office Building, #720 Washington, D.C. 20510 Re: S. 2723 –The Mitigating Emergency Drug Shortages (MEDS) Act Dear Senator Collins and Senator S
Advocacy and Issues
Drug Shortages
Legislative Advocacy Addressing America's Drug Shortage Crisis [11/05/19] ASHP Supports the Mitigating Emergency Drug Shortages (MEDS) Act [10/28/19] Drug Shortage Legislative Objectives [08/28/19] ASHP Applauds Senators and Expresses Support for Drug Shortages Task Force [06/21/
Drug Shortages
FDA and ASHP Shortage Parameters
FDA ASHP Purpose Provides information obtained from manufacturers about current shortages, estimated duration, and discontinuations and provides information about FDA’s and other stakeholders’ roles in ad
Drug Shortages
Guidelines and Tools
Best Practices and Guidelines ASHP Guidelines on Managing Drug Product Shortages [Updated July 2018] Sample Drug Shortages Policy by University Healthcare Hospitals and Clinics [PDF] FDA Drug Shortages Website CDC Vaccine Shortages Website Tools Small Volume Parenteral (SVP) Solutions Shortages: Su
Drug Shortages
Injectable Opioid Survey Report
Impact of Injectable Opioid Shortage and Update on Small-Volume Parenteral Solution Supplies Survey Report Survey conducted April 2018. ASHP surveyed its members to assess the recovery of the small-volume parenteral (SVP) solution shortage and to assess the impact of the acute shortage of injectable
Advocacy and Issues
ASHP Expresses Concern for Drug Shortages in Comments on Controlled Substances Quotas Proposed Rule
[Submitted electronically via www.regulations.gov] Drug Enforcement Administration Attn: DEA Federal Register Representative/DRW 8701 Morrissette Drive Springfield, VA 22152 RE: Controlled Substances Quotas [Docket No. DEA-508P] The undersigned groups thank the Drug Enforcement Administratio
Advocacy and Issues
“Developments in the Prescription Drug Market” February 4, 2016
ASHP (American Society of Health-System Pharmacists) respectfully submits the following statement for the record to the House Committee on Oversight and Government Reform hearing on "Developments in the Prescription Drug Market: Oversight." ASHP represents pharmacists who serve as patient care provi
Advocacy and Issues
Drug Pricing
Health Care Transparency Executive Order Drug Pricing --> Addressing the issue of skyrocketing drug prices, including excessive price increases on commonly used generic medications and significant increases charged by pharmacy benefit managers (PBMs), is one of ASHP’s highest and longstanding
Advocacy and Issues
Drug Shortage Legislative Objectives
ASHP continues to work with members of Congress to craft comprehensive legislation to end drug shortages. ASHP, along with our partners, the American Hospital Association, American Society of Clinical Oncology, and the American Society of Anesthesiologists, has developed legislative objectives based
Advocacy and Issues
ASHP Expresses Support for Drug Shortages Task Force
The Honorable Chris Murphy United States Senate 136 Hart Senate Office Building Washington, D.C. 20510 Dear Senator Murphy, ASHP (the American Society of Health-System Pharmacists) applauds your leadership on a recent letter to the Food and Drug Administration (FDA) urging the agency to create a Dr